Sylver Quevedo, MD discusses clinical use of psychedelics, the biologic mechanisms of psilocybin, MDMA, ketamine, ayahuasca and how these substances differ in effect and psychotherapeutic use for alleviating PTSD, depression, anxiety and chronic pain
Psychedelic-assisted interventions appear to be all the rage these days. Though there are many psychedelic evangelists I wanted to find a credible medical resource to discuss these treatments. Deep gratitude to my friend Ron Purser who introduced me to my esteemed guest, Sylver Quevedo, MD, a pioneer in integrative family and internal medicine, assistant professor of medicine at Stanford and UCSF, co-Founder of Polaris Insight Center for Ketamine-assisted psychotherapy, and Principle Investigator in the FDA clinical trials on MDMA for Post-traumatic Stress Disorder. Our conversation was enlightening and it was fascinating to hear about Dr. Quevedo’s long history of work in public health, his devotion to providing medical care for indigenous populations in the American Southwest and Africa, and his enduring personal and professional interest in clinical use of psychedelic plant medicines. He beautifully explicates the biologic mechanisms of psilocybin, MDMA, ketamine, ayahuasca, mescaline and how these substances differ in effect and usefulness in psychotherapy. Dr. Quevedo is limited in discussing outcomes of the current phase 3 MDMA trials but he shared results of previous MDMA for PTSD trials, as well as use of psilocybin-assisted psychotherapy for end-of-life anxiety, depression, and ketamine-assisted psychotherapy for suicidal depression and chronic pain. So sit back and enjoy the journey this amazing physician takes us on.
https://maps.org Multidisciplinary Association for Psychedelic Studies
https://clinicaltrials.gov/ NIH MDMA Studies
Sylver Quevedo, MD, Internist Polaris Co-Founder and Medical Director has been in continuous practice of medicine for 40 years and practices nephrology, family, internal, and integrative medicine. He serves as Assistant Professor at Stanford and UCSF. He has played pivotal roles in several global health projects, including planning and development of medical and nursing school in Africa. The staff at Polaris Insight Center are dedicated to the ethical and compassionate clinical use of ketamine-assisted, and psychedelic-assisted, psychotherapy. Our founding members are all MAPS (Multi-disciplinary Association for Psychedelic Studies) trained clinicians who have participated in both Phase 2 and Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD.